IFLR1000

Eli Lilly $1.6 billion acquisition of ARMO Biosciences

10/5/2018
Public acquisition
Select tab

$ 1.6 billion

Announced

10/5/2018

Overview:

  • Pharmaceutical company Eli Lilly has acquired ARMO Biosciences in a $1.6 billion deal. 
  • Credit Suisse acted as financial adviser for Eli Lilly and Centerview Partners and Jefferies advised ARMO. 
  • The transaction is expected to close in the second quarter of 2018. 

Kurt Stumpo - Journalist

Jurisdiction:

United States

Deal type:

Public acquisition

Practice area:

M&A

Governing law:

United States

Industry sector:

Pharmaceuticals and life sciences

Firms:
Gunderson Dettmer

Party: ARMO Biosciences (Target)

Lawyers: Andrew Luh, Marcia Hatch

Wachtell Lipton Rosen & Katz

Party: Eli Lilly (Acquirer)

Related deals